Compare Ginkgo Bioworks Holdings Inc (DNA) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Upwork Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Upwork Inc trades at $8.6 (market cap $1.07B). The key difference: Upwork Inc is the larger of the two by market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Upwork Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Upwork Inc for 38 Days on average.
| DNA | UPWK | |
|---|---|---|
Market Cap | $763.64M | $1.07B |
Volume | 3,204,177 | 2,574,130 |
Sector | Health | Industrials |
52-Week High | $15.83 | $22.11 |
52-Week Low | $5.48 | $7.84 |
Typical Hold Time | 7 Days | 38 Days |
Enterprise Value | $865.59M | $833.01M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with negative cash flow. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting ongoing strategic initiatives despite financial challenges.
The outlook remains speculative given persistent losses and cash burn, though analyst consensus is divided. Key risks include execution on revenue growth and path to profitability. Upside depends on successful commercialization of its biotech platform and partnerships, but high volatility and fundamental weakness warrant caution for investors.
UPWK trades at $8.57, up 2.02% today, but the technical outlook is bearish with resistance near $9. The company reported Q2 2026 earnings that beat estimates, with revenue of $191.7M and adjusted EBITDA of $64.1M (MarketBeat, August 10, 2026), but issued weak guidance causing a 13% stock drop (Invezz, August 11, 2026). Fundamentals show strong profitability with a 77.21% gross margin and a P/E of 10.99, though net income declined to $115.43M in 2025 from $216M in 2024.
The stock presents a mixed outlook: valuation appears attractive with analyst consensus target of $9.64 (12.5% upside), but risks include AI-driven disruption to freelance demand, insider selling, and ongoing securities fraud investigations (GlobeNewswire, September 2026). Investor sentiment is cautious despite a majority buy rating from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
